| 2022 Presidential Trainee Award Recipients |
|
|
|
|
 Mari Cayabyab, PharmD University of California, San Francisco PT-003 - CORONARY HEART DISEASE POLYGENIC RISK SCORE MODIFIES STATIN RELATIVE RISK REDUCTION FOR THE PRIMARY PREVENTION OF MYOCARDIAL INFARCTION IN A REAL-WORLD COHORT 2022 Jason Morrow, MD, Presidential Trainee Award Recipient |
 Vincent Chang, BSc University of California, San Francisco PT-004 - PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF PRIMARY CLINICAL OUTCOMES IN TREATING DRUG-SENSITIVE TUBERCULOSIS WITH FOUR-MONTH HIGH-DOSE RIFAPENTINE WITH AND WITHOUT MOXIFLOXACIN (STUDY 31/A5349) |
 Joseph Collins, PhD University of Florida PT-005 - IDENTIFICATION OF A DISTAL ENHANCER AND REGULATORY VARIANTS CONTROLLING EXPRESSION OF THE CYP3A GENES |
 Yizhen Guo, PharmD The Ohio State University PT-006 - HYPOALBUMINEMIA EARLY IN TREATMENT HINDERS BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED CANCERS |
 Emma Hughes, BA University of California, San Francisco PT-007 - OPTIMIZING DIHYDROARTEMISININ-PIPERAQUINE REGIMENS FOR MALARIA PREVENTION IN PREGNANT WOMEN USING REPEATED ECG AND PARASITE DENSITY MEASURES |
 Noor A. Nahid, MS University of Florida PT-008 - PHARMACOGENOMIC GENOME-WIDE META-ANALYSIS TO IDENTIFY VARIANTS ASSOCIATED WITH THIAZIDE AND THIAZIDE-LIKE DIURETIC INDUCED GLUCOSE CHANGE |
 Mahesh Nepal, PhD The Ohio State University PT-009 - PREVENTION OF OXALIPLATIN NEUROPATHY BY DULOXETINE-MEDIATED OCT2 INHIBITION |
 Huy Ngo, PharmD, PhD University of California, San Francisco PT-010 - WEIGHT-BASED DOSING IS NOT NEEDED FOR RIFAMPICIN FOR PATIENTS WITH TUBERCULOSIS (TB): PK EVIDENCE FROM TBTC STUDY S31/A5349 (STUDY S31) |
 Anh Nguyen, PharmD University of North Carolina at Chapel Hill PT-011 - INVESTIGATION OF CARDIOVASCULAR OUTCOMES IN BLACK PATIENTS FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD CLINICAL SETTING |
 Nam Nguyen, PharmD University of Florida PT-012 - PHARMACOGENOMIC SINGLE NUCLEOTIDE POLYMORPHISM (SNP) SCORES AS A TOOL TO PREDICT TOXICITY PHENOTYPES IN TREATMENT OF ACUTE CHILDHOOD LEUKEMIA (ALL) 2022 David J. Goldstein, MD, PhD, Presidential Trainee Award Recipient |
 Thanh Thanh Nguyen, BA Mayo Clinic PT-013 - CORTISOL REGULATES ALTERNATIVE POLYADENYLATION IN A GENOTYPE-DEPENDENT MANNER: GLUCOCORTICOID-DEPENDENT PHARMACOGENOMIC ALTERNATIVE POLYADENYLATION QUANTITATIVE TRAIT LOCI (PGx-3’aQTLs) |
 Trang Nguyen, PharmD University of Florida PT-014 - RISK STRATIFICATION WITH PRE-TREATMENT METABOLITE RISK SCORE FOR CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS |
 Keyur Parmar, MS Takeda PT-015 - CHARACTERIZATION OF CAR-T CELLULAR KINETICS AND EFFICACY IN PATIENTS WITH SOLID TUMORS IN PRESENCE OR ABSENCE OF PRIOR LYMPHODEPLETION CHEMOTHERAPY USING A PBPK-PD MODEL |
 Julia Quintanilha, PharmD, PhD University of North Carolina at Chapel Hill PT-016 - POLYGENIC RISK SCORES FOR BLOOD PRESSURE MAY PREDICT RISK OF SEVERE BEVACIZUMAB-INDUCED HYPERTENSION IN CANCER PATIENTS |
 Sarah Ridge, PhD US Food and Drug Administration PT-017 - CLINICAL PHARMACOLOGY POSTMARKETING STUDIES: A US FDA EVALUATION OF KNOWLEDGE GAPS AND TRANSLATION INTO LABELING |
 Vivek Shastri, PhD University of Florida PT-018 - A POLYGENIC DNA DAMAGE REPAIR PHARMACOGENOMICS (DDR_PGX) SCORE PREDICTS RESPONSE TO GEMTUZUMAB OZOGAMICIN IN PEDIATRIC AML PATIENTS |
 Shawn Pei Feng Tan, BS The University of Manchester PT-019 - UNCOVERING THE DISPROPORTIONAL IMPACT OF CHRONIC KIDNEY DISEASE ON THE RENAL SECRETION OF DRUGS VIA ORGANIC ANION TRANSPORTERS (OAT) 1 AND 3 |
 Cameron Thomas, PharmD University of Florida PT-020 - IMPACT OF CYP2C19 GENOTYPE ON PREDICTION OF CARDIOVASCULAR EVENTS WITH THE ABCD-GENE SCORE AMONG PATIENTS RECEIVING CYP2C19-GUIDED ANTIPLATELET THERAPY AFTER PCI |
 Angelia Wang, BS, MS Takeda PT-021 - DEVELOPMENT OF A TRANSLATIONAL PBPK-PD FRAMEWORK TO CHARACTERIZE CELLULAR KINETICS AND BIODISTRIBUTION OF CAR-T CELLS IN MICE AND CANCER PATIENTS |
|
.png)
